Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
3SBio ( (HK:1530) ) just unveiled an update.
3SBio Inc. announced that its anti-VEGF/PD-1 bispecific antibody, known as 707 Injection, has been granted Breakthrough Therapy Designation by China’s National Medical Products Administration for the first-line treatment of PD-L1 positive locally advanced or metastatic non-small cell lung cancer. This designation will accelerate the drug’s development and potential market launch, reflecting 3SBio’s strengthened position in the oncology sector and its commitment to advancing cancer treatment options.
More about 3SBio
3SBio Inc. is a biotechnology company focused on developing and manufacturing biopharmaceutical products. The company specializes in innovative therapies, particularly in the field of oncology, with a market focus on China and international markets.
YTD Price Performance: 25.97%
Technical Sentiment Signal: Sell
Current Market Cap: $3.86B
See more insights into 1530 stock on TipRanks’ Stock Analysis page.